– USA, CA – ALX Oncology Holdings Inc., (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, announced the appointments of Dr. Barbara Klencke (M.D.) and Dr. Chris Takimoto (M.D., Ph.D., FACP) to its Board of Directors.
“I look forward to working with Barbara and Chris on the Board of Directors,” said Board Chairman, Dr. Corey Goodman. “Their expertise in cancer research and in the development of innovative oncology therapies across all stages of R&D – from discovery to regulatory approval and commercialization – make them exceptional additions and assets to the ALX Oncology Board.”
Additionally, the company also announced the appointment of Harish Shantharam as CFO.
About Dr. Barbara Klencke
Dr. Klencke has over 30 years of experience in patient care, academic and scientific research, and clinical drug development in hematology and oncology. She has deep R&D expertise and has made significant contributions to the development, approval, and commercialization of numerous oncology products through various executive leadership roles at a range of small, mid-size, and large biotech companies including Sierra Oncology, Onyx Pharmaceuticals, and Genentech, a member of the Roche Group. Before entering the biotechnology industry, Dr. Klencke served as an Assistant Clinical Professor of Medicine at, the Division of Hematology and Oncology, at the University of California, San Francisco, where she previously completed her training in hematology, oncology, and internal medicine.
Dr. Barbara Klencke holds a Bachelor of Science degree from Indiana University and an M.D. from the University of California, Davis. She is an independent board director of Xencor, TScan Therapeutics and Immune-Onc Therapeutics.
About Dr. Chris H. Takimoto
Dr. Takimoto has over 30 years of experience in oncology and pharmacology through a distinguished career across academia, industry, and, public service. As a cancer researcher and drug developer, he has spearheaded the clinical development of numerous oncology products. Dr. Takimoto serves as Global CMO at the START Center for Cancer Research. Previously, he served as CMO at IGM Biosciences and Forty Seven through its acquisition by Gilead for $4.9 billion, and as SVP of Oncology at Gilead Sciences. PrioBeforet held roles of increasing responsibility in oncology drug development at Janssen/Johnson & Johnson. Dr. Takimoto was also an independent board director for Tizona Therapeutics. He has held academic positions at the University of Texas Health Science Center at San Antonio, the National Cancer Institute, and, the Uniformed Services University of the Health Sciences, and he has served as a Commissioned Officer in the U.S. Public Health Service.
Dr. Takimoto completed his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in oncology at the National Cancer Institute. He received a Bachelor of Science degree in chemistry from Stanford University, a Ph.D. in pharmacology from Yale University, and an M.D. from Yale University School of Medicine.
About Harish Shantharam
Mr. Shantharam has over 20 years of experience in financial and commercial functions at a broad range of biotech and biopharmaceutical companies at various stages of growth and market capitalization. His expertise spans finance strategy and operations, commercialization, capital markets engagement, and business development. Most recently, he served as CFO at CymaBay Therapeutics, where he helped guide the company in its transition towards late-stage development and commercial readiness and through its $4.3 billion acquisition by Gilead Sciences. Earlier in his career, he served in roles of increasing responsibility and scope at Gilead Sciences, including as VP and Head of Global Commercial Finance, when he led the financial operations supporting a $20-30 billion dollar revenue business globally. While at Gilead, he also led business development activities for finance for several strategic acquisitions and supported numerous major new product launches in financial and commercial operations capacities. Before Gilead, Mr. Shantharam served in various roles of increasing responsibility for driving forecasting, commercial analytics,s, and business development at Amgen.
Harish Shantharam holds an MBA in finance from UCLA Anderson School of Management and a graduate degree in Industrial Engineering from the University of Texas at Arlington. He is also a CFA charter holder.
About ALX Oncology
ALX Oncology is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated the potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications.
For more information: https://alxoncology.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.